SCHEMBL4523845

SCHEMBL4523845

COC(=O)COc1cccc(/C=C/C(=O)c2c(C)[nH]c(O)cc2=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 1/20 0.47
CYSLTR1 Q9Y271 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
MAPT P10636 2/20 0.45
RAB9A P51151 2/20 0.45
POLB P06746 1/20 0.45
ABCG2 Q9UNQ0 3/20 0.44
NQO1 P15559 2/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAOB P27338 2/20 0.42
MAOA P21397 1/20 0.42
BCHE P06276 1/20 0.41
NR1H4 Q96RI1 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
LMNA P02545 1/20 0.41
CYP1A1 P04798 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523850 1.00 CYSLTR2 (0.47) CYSLTR2CYSLTR1SMN1; SMN2NPC1MAPT
SCHEMBL4515466 0.90 ACMSD (0.48) CYSLTR2CYSLTR1SMN1; SMN2NPC1MAPT
SCHEMBL4515474 0.90 ACMSD (0.48) CYSLTR2CYSLTR1SMN1; SMN2NPC1MAPT
SCHEMBL13818119 0.87 CYSLTR2 (0.46) CYSLTR2CYSLTR1SMN1; SMN2MAPTABCG2
SCHEMBL2279961 0.83 ABCG2 (0.48) CYSLTR2CYSLTR1SMN1; SMN2MAPTABCG2
SCHEMBL2279958 0.83 ABCG2 (0.48) CYSLTR2CYSLTR1SMN1; SMN2MAPTABCG2
SCHEMBL4518410 0.82 LMNA (0.56) CYSLTR2CYSLTR1SMN1; SMN2MAPTPOLB
SCHEMBL4518413 0.82 LMNA (0.56) CYSLTR2CYSLTR1SMN1; SMN2MAPTPOLB
SCHEMBL2276772 0.80 ABCG2 (0.47) CYSLTR2CYSLTR1SMN1; SMN2NPC1MAPT
SCHEMBL2276769 0.80 ABCG2 (0.47) CYSLTR2CYSLTR1SMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
EP-1857104-A1 USE OF CINNAMOYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143368-A1 Use of Cinnamoyl Compound COL2A1, COL1A1, SMAD2 CYSLTR2 1079/4885CYSLTR1 1024/4885SMN1; SMN2 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.